---
title: "Weekly Recap | Vaxcyte -10.87%, consensus target above spot"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/302174347.md"
description: "Vaxcyte (PCVX) fell 10.87% this week to close at $63.62, underperforming the S&P 500 by roughly 8.92 percentage points. The stock faded after an early high: it touched $72.89 on Monday, then drifted lower through the week, hitting $62.54 on Friday and closing near the 60-day moving average of $60.078. Weekly amplitude came to 14.56% on volume of 12.30 million shares, about double the recent average."
datetime: "2026-10-17T07:58:07.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/302174347.md)
  - [en](https://longbridge.com/en/news/302174347.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/302174347.md)
generator: "portal-rs"
---

# Weekly Recap | Vaxcyte -10.87%, consensus target above spot

## The Week

Vaxcyte (PCVX) fell 10.87% this week to close at $63.62, underperforming the S&P 500 by roughly 8.92 percentage points. The stock faded after an early high: it touched $72.89 on Monday, then drifted lower through the week, hitting $62.54 on Friday and closing near the 60-day moving average of $60.078. Weekly amplitude came to 14.56% on volume of 12.30 million shares, about double the recent average.

## Key Events

Company-specific flow this week was built mainly around analyst views. Cantor Fitzgerald reiterated its rating twice on Monday, keeping a buy or overweight stance with a $120 price target. Media coverage meanwhile focused on the pneumococcal vaccine programme, with reports noting that Vaxcyte shares have delivered gains of 100% or more as the programme has advanced, while the week itself brought a clear pullback.

## Analyst Ratings

Coverage currently stands at 11 brokers: 9 rate the stock a buy, 1 an overweight, and 1 a hold, with no sell or underweight ratings, putting the consensus at strong buy. The consensus target price is $117.3, roughly 84.38% above the latest close, and the target range runs from $75 to $163, pointing to a wide dispersion of views. Within the 509-company biotechnology sector, the ratings rank sits in the middle at 129th.

## The Week Ahead

Macro data from the US picks up next week: the NAHB housing market index arrives on Monday, housing starts and building permits on Tuesday, and EIA weekly crude inventories on Wednesday. Vaxcyte has no scheduled earnings or major company events, so progress on the pneumococcal vaccine programme remains the main stock-specific item to watch.

## In Short

Vaxcyte’s price action this week sits in tension with the broker view: most institutions rate it buy, and the consensus target sits well above spot, yet shares dropped more than 10% this week. The latest session’s flow showed small-lot money as a net buyer while large-lot money was a net seller, underlining a divided tape. The question ahead is whether the stock can hold around the 60-day moving average and what the vaccine programme delivers next.

*This article is generated by LongbridgeAI from market data, for information only and not investment advice.*

### Related Stocks

- [PCVX.US](https://longbridge.com/en/quote/PCVX.US.md)

## Related News & Research

- [Vaxcyte, Inc. $PCVX Shares Sold by Banque Pictet & Cie SA](https://longbridge.com/en/news/302252273.md)
- [Insider Selling: Vaxcyte (NASDAQ:PCVX) CAO Sells $1,648,060.00 in Stock](https://longbridge.com/en/news/301253547.md)
- [Vaxcyte closes USD 650 million convertible senior notes offering](https://longbridge.com/en/news/301435744.md)
- [Vaxcyte Announces Commencement Of Proposed Public Offerings Of Common Stock, Pre-Funded Warrants And Convertible Senior Notes](https://longbridge.com/en/news/300969941.md)
- [BUZZ-Vaxcyte surges on pneumococcal vaccine late-stage trial success](https://longbridge.com/en/news/300919546.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**